Regeneron Pharmaceuticals, Inc.
Explore Regeneron Pharmaceuticals, Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
CorpDigest
Regeneron Pharmaceuticals, Inc.
Explore Regeneron Pharmaceuticals, Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
Annual Revenue
FY2024 Revenue
$14.2B
▲ 8.3% vs FY2023 ($13.1B)
Source: Annual report / company filing
Regeneron Pharmaceuticals, Inc. reported $14.2B in revenue for fiscal year 2024. This represents a growth of 8.3% compared to the 2023 figure of $13.1B. In 2025, revenue increased to $14.3B.
Revenue climbed 8.3% to $14.2 billion in 2024 as Dupixent profit share and EYLEA HD growth offset declines in the original EYLEA formulation facing biosimilar pressure.
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.